ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s ACARIZAX® tablet for use in children,…
Program supports women entrepreneurs in life science who are driving the advancement of innovations and healthcare TORONTO, March 6, 2025…
Los Angeles, California--(Newsfile Corp. - March 6, 2025) - The St. Baldrick's Foundation, the largest charity funder of childhood cancer…
The Roddenberry Foundation is building the medically-advanced future Star Trek envisioned LOS ANGELES, March 5, 2025 /PRNewswire/ -- The Roddenberry Foundation…
Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts…
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter…
Nes-Ziona, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…
Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease in bone/bone marrowNEW…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR…
This collaboration will expand Comprehensive Cell Solutions, a business unit of NYBCe, capabilities and geographic reach as a contract development…